Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 5c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vanda Pharmaceuticals (VNDA) PT Raised to $13 at Cantor Fitzgerald
August 1, 2024 6:35 AM EDTCantor Fitzgerald analyst Charles Duncan raised the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $13.00 (from $11.00) while maintaining a Overweight rating.
The analyst comments "Overall, we see VNDA as a differentiated Neuro-Innovator with a broadening neuropsych portfolio that should garner investors' interest as... More
